



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/53, 33/68, C12Q 1/68		A1	(11) International Publication Number: WO 95/27901
			(43) International Publication Date: 19 October 1995 (19.10.95)
(21) International Application Number:	PCT/US95/04509	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date:	10 April 1995 (10.04.95)		
(30) Priority Data:	08/227,101 11 April 1994 (11.04.94) US		
(71) Applicant:	IXSYS, INC. [US/US]; 3550 Dunhill Street, San Diego, CA 92121 (US).	Published <i>With international search report.</i>	
(74) Agents:	GAY, David, A. et al.; Campbell and Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		
(54) Title: CLASS I PEPTIDE BINDING MOTIFS			
(57) Abstract			
<p>The present invention provides methods to identify peptides capable of forming a loaded MHC molecule by generating a library of random peptides greater than 8 residues in length expressed as fusion proteins on the surface of a cell or virus screening the fusion proteins for binding to unbound MHC molecules and obtaining the terminal octamers or nonamers therefrom. Additionally, the sequence of amino acids adjacent to the terminal octamers or nonamers which permit binding can be identified, and a library of these tether sequences bound to random octamers or nonamers generated. The invention also provides a method of chemically modifying the N-terminal amino acids of a random display library, as by formylation.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CLASS I PEPTIDE BINDING MOTIFS

BACKGROUND OF THE INVENTION

This invention relates to the immune system, and more specifically, to peptides which mediate an immune response.

The immune system has evolved to vertebrates from 5 invasion from micro-organisms and larger parasites which are recognized as foreign. There are two broad categories of immune response: antibody responses and cell-mediated responses. The latter involves the production of specialized cells that react with foreign materials, or 10 antigens, on the surface of other host cells. Among these reacting cells are cytotoxic T cells, which recognize and kill virus infected cells and virus induced cancers. T cells bind to foreign antigen only when it is associated on the surface of a presenting cell with a special class of 15 cell surface glycoproteins known as MHC (major histocompatibility complex) molecules. This ensures that T cells are activated only when they contact another host cell.

Class I MHC molecules are found in all nucleated 20 cells. These molecules comprise a single transmembrane polypeptide chain called L, which is non-covalently associated with an extracellular, non-glycosylated small protein called β_2 microglobulin (IB2M).

Cytotoxic T lymphocytes recognize and are 25 activated peptides which are derived from proteins synthesized intracellularly and presented at the cell surface by MHC class I molecules. These cells play a primary role in immune surveillance by responding to changes in the composition of the pool of endogenous 30 peptide which occurs following infection by intracellular invaders such as parasites or viruses, or concomitant with cell transformation. The identity and composition of the

peptides which bind to MHC class I molecules in large measure determine the range of possible peptide epitopes.

Sequencing of peptides which bind to the antigen binding groove class I heterodimers has identified size and 5 sequence motif restrictions for class I molecules, and reveals the presence of one or two very conserved 'anchor residue' positions for each of the class I molecules examined. In general, MHC class I binding peptides must be 8 or 9 amino acids in length in order to bind to the 10 groove. Class I-peptide cocrystal studies on human and mouse complexes have determined that the N-terminal end of bound peptides are buried in the peptide binding cleft, whereas the C-terminal end is held relatively close to the surface by a salt bridge. Additions of residues to the 15 peptide N-terminus are not tolerated.

There exists a need to provide peptides able to bind to MHC Class I molecules in order to mediate cytotoxic T cell activation. The present invention satisfies this need and provides related advantages as well.

20

SUMMARY OF THE INVENTION

The present invention provides methods to identify peptides capable of forming a loaded MHC molecule by generating a library of random peptides greater than 8 residues in length expressed as fusion proteins on the 25 surface of a cell or virus screening the fusion proteins for binding to unbound MHC molecules and obtaining the terminal octamers or nonamers therefrom. Additionally, the sequence of amino acids adjacent to the terminal octamers or nonamers which permit binding can be identified, and a 30 library of these tether sequences bound to random octamers or nonamers generated. The invention also provides a method of chemically modifying the N-terminal amino acids of a random display library, as by formylation.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig 1 Panning of peptide phage library:

A) Latex beads are coupled to antibody that binds to a peptide tag cloned onto the soluble MHC class I molecule.
5 B) The empty soluble class I molecule is captured onto the bead by binding the peptide tag on the class I molecule to the antibody directed against the tag that was previously attached to the bead. C) The phage expressing desired fusion peptides are captured by incubating the phage library with the beads attached to the empty soluble class I molecule. The uncaptured phage are then washed away 10 leaving the phage expressing the desired peptide fusion protein.

Fig 2) Screening Panned Phage Library A) Bacteria are 15 infected the panned phage library while still attached to the latex beads. and grown on a bacterial lawn until the phage form visible plaques in the bacterial lawn. B) A filter containing 10 mM IPTG is placed onto the bacterial lawn for several hours. Peptides from the phage plaques 20 attach to the Nitrocellulose filter in discreet spots which correspond to the phage plaques on the bacterial lawn. This filter is blocked with a high protein solution and incubated with empty soluble Class I molecules for several hours.

25

Fig 3) Incubation of the Plaque lifts with Enzyme-linked antibody: A) The filters which have been incubated with empty soluble Class I molecules have these molecules attached to the spots containing the peptides of interest 80 and an antibody that has been previously coupled to calf intestine alkaline phosphatase is added. This antibody attaches to the peptide tag to the spots containing peptides of interest. The filter is then developed.

Fig 4) Interpretation of the developed filters. After development the filters have dark spots where the antibody coupled to alkaline phosphatase is attached to the filter. Two different classes of peptides can bind the AP conjugated antibody. the ones that bound to the filter with the class I molecule as an intermediate. These are the true positives. It is also possible that the AP conjugated antibody binds directly to a peptide phage fusion protein. These are false positives. These false positives can be eliminated by taking a second nitrocellulose lift from the same bacterial lawn and processing as described omitting the addition of empty class I molecules. All of the false positives will be positive on the second filter lift. The spots that are positive on the first lifts but not the second are true positives.

Fig 5) The peptide sequence of phage clones selected with Kb: VSV-8 OVA-8 and SEV-9 are peptides that have been previously determined to bind the Kb molecule. The peptide sequences below the dashed line are all newly identified peptide sequence that bind to soluble empty Kb molecules.

Fig 6) The peptide sequence of phage clones selected with Kbml: The peptide sequences below the dashed line are all newly identified peptide sequences that bind to soluble empty Kbml molecules.

Fig 7) The peptide sequence of phage clones selected with Kbml8: The peptide sequences below the dashed line are all newly identified peptide sequences that bind to soluble empty Kbml8 molecules.

Fig 8) The N-formylation of phage displayed peptides: A library of phage expressed peptides is N-formylated with 1-

ethyl-3-(3-dimethylaminopropyl)carbodiide hydrochloride (EDC).

Fig 9) Phage filter lifts assay compared to solution peptide competition studies.

5 Fig 10) Phage-displayed peptides selected with empty soluble Hmt molecules: The peptides sequences below the dashed line are all newly identified peptides sequences that bind to soluble empty Hmt molecules after the peptide library had been N-formylated but not before it had been
10 modified.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for identifying peptides capable of binding to MHC molecules. A library of random peptides is synthesized, for example as
15 fusion proteins in the surface of a cell or virus. The fusion peptides are longer in length than the 8 or 9 amino acid peptides (octamers and nonamers) known to fit into the MHC Class I pocket and are preferably greater than about 8 or greater than 10 amino acids. These fusion proteins are
20 then screened for binding to MHC Class I molecules. In one embodiment, empty MHC molecules (not containing a peptide) are expressed on insect cells. The motifs within the terminal 8 or 9 amino acids are identified to provide peptides capable of MHC Class I binding and T cell
25 activation. These octomers or nonamers are termed MHC binding peptides.

In a further embodiment, amino acid sequences in the "tether" domain -- the amino acids positioned between the MHC binding domain and the fused viral or bacterial
30 protein -- are identified. Certain sequences permit the attached MHC binding domain to bind the MHC Class I molecules. Libraries of peptides containing random

octamers and nonamers attached to permissive tether sequences can in turn be synthesized and screened.

In another embodiment, the N-terminus of the fusion peptide can be modified, as by formylation, while 5 the fusion peptide is displayed on the virus or cell surface. The invention provides libraries of such N-terminally modified fusion proteins.

As used herein, the term "MHC binding domain" means the MHC antigen binding groove found between the α_1 10 and α_2 alpha helices. The base of the groove is formed by 8 β sheets from the same domains.

As used herein, the term "empty MHC molecules" means an empty MHC Class I molecule without a peptide in 15 the antigen binding groove.

As used herein, the term "unbound MHC molecule" 20 is a MHC class I molecule with a peptide in its antigen binding site.

As used herein, the term "peptide tether" means a amino acids just proximal to the carboxy terminal amino 25 acid of a peptide loaded into the MHC Class I molecule antigen binding groove.

Peptide binding motifs have been identified for several MHC class I molecules by screening codon-based random peptide phage display libraries with empty soluble 25 mouse MHC class I molecules produced in *D. melanogaster*. We have identified peptide binding motifs for several MHC class I molecules by screening codon-based random peptide phage display libraries with soluble empty class I- β_2m complexes. This method allows evaluation of the chemical 30 interactions of multiple individual peptides with a class I peptide binding site, and results in the identification

of binding motifs which are based on numerous discrete peptide binding events. This rapid method identifies peptide tetra residues, provides sequence information on neighboring amino acids and relationships between amino 5 acids within the peptides, and reveals a preference for several amino acids at peptide positions previously thought to be indiscriminate. This approach does not incorporate the bias inherent in methods which depend upon cellular protease peptide transport and processing specificities, 10 and differs from methods which generate a statistical picture of amino acid representation from heterogeneous peptide fractions at positions from the peptide N-terminus.

Peptide binding motifs for H-2K^b differ significantly from the H-2K^{bml} motif, consistent with data 15 from biological function assays. Competition binding studies with soluble peptides confirm the differential binding information obtained from filter lift assays of phage-displayed peptides and provide support for filter binding sensitivity in the hundred nanomolar range.

20 Chemical formylation of phage prior to panning and following plaque lifts allows screening with the Hmt class I molecule and identifies amino acid residues which are critical for Hmt binding. Codon-based random peptide phage display libraries limit redundancy in amino acid 25 representation, and allow the screening of a representative number of library members with empty soluble MHC class I molecules, thus utilizing the powerful combination of genetics and biochemistry to rapidly identify MHC class I binding motifs.

30 The murine K^b molecule is one of the most extensively examined of the 'classical' MHC class I molecules. Peptides eluted from cellular K^b complexes have provided sequence information on self peptides, viral peptides, and epitopes derived from exogenous proteins. 35 The K^b processed-peptide binding motif ads described

includes aromatic anchor residues (Y or F) at the third and fifth positions from the N-terminus, and C-terminal hydrophobic (M, I, V or L) anchor residue. However, these results incorporate the possible selective effects of 5 peptide processing and transport in addition to the requirements necessary for binding.

The method has identified a strong correlation of binding with the presence of aromatic amino acid residues at peptide positions P3 and P5 (92% and 97% of clones, 10 respectively). In addition, the method identifies a preference for valine, isoleucine and serine residues at the peptide N-terminus (84%); When the N-terminal amino acid is serine, isoleucine appears frequently (64%) at the P2 position (second from the N-terminus), and phenylalanine 15 appears to be favored at the P5 position (91%). When the peptide P5 position is a phenylalanine there is little specificity associated with the P6 amino acid residue; however, when this P5 position is a tyrosine residue, smaller glycine or serine residues predominate at the 20 flanking P6 position (89%). This method has identified peptide clones with features consistent with natural peptide epitopes. For example, the D9 clone, SIIIFYWT, closely resembles the Ova-8 epitope, SIINFEKL.

Clones with the best relative signals generally 25 have one of the following two characteristics: an N-terminal valine or isoleucine followed by a glycine or serine residue at P2, aromatic residues at positions P3 and P5, and an amino acid at P6 which has a smaller side chain (glycine or serine); alternatively, an N-terminal serine is 30 followed by an isoleucine at position P2, a tyrosine or isoleucine at position P3, and a phenylalanine residue at P5.

EXAMPLE I

EXPRESSION OF RANDOM PEPTIDE LIBRARY

A library of random peptides each containing 22 amino acids was synthesized as fusion peptides displayed on the phage sequence according to the methods described in U.S. Patent No. 5,264,563 issued November 23, 1993 and WO 92106176, published 16 April 1993, which are incorporated herein by reference. Briefly, the synthesis of two randomized oligonucleotides which correspond to smaller portions of a larger randomized oligonucleotide is shown below. Each of the two smaller portions make up one-half of the larger oligonucleotide. The population of randomized oligonucleotides constituting each half are designated the right and left half. Each population of right and left halves are ten codons in length with twenty random codons at each position. The right half corresponds to the sense sequence of the randomized oligonucleotides and encode the carboxy terminal half of the expressed peptides. The left half corresponds to the anti-sense sequence of the randomized oligonucleotides and encode the amino terminal half of the expressed peptides. The right and left halves of the randomized oligonucleotide populations are cloned into separate vector species and then mixed and joined so that the right and left halves come together in random combination to produce a single expression vector species which contains a population of randomized oligonucleotides twenty codons in length. Electroporation of the vector population into an appropriate host produces filamentous phage which express the random peptides on their surface.

The reaction vessels for oligonucleotide synthesis were obtained from the manufacturer of the automated synthesizer (Millipore, Burlington, MA; supplier of MilliGen/Bioscience Cyclone Plus Synthesizer). The vessels were supplied as packages containing empty reaction columns (1 μmole), frits, crimps and plugs

(MilliGen/Bioscience catalog # GEN 860458). Derivatized and underivatized control pore glass, phosphoramidite nucleotides, and synthesis reagents were also obtained from MilliGen/Bioscience. Crimper and decrimper tools were 5 obtained from Fisher Scientific Co., Pittsburgh, PA (Catalog numbers 06-406-20 and 06-406-25A, respectively).

Ten reaction columns were used for right half synthesis of random oligonucleotides ten codons in length. The oligonucleotides have 5 monomers at their 3' end of the 10 sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 5'AATTCCAT3'. The synthesizer was fitted with a column derivatized with a thymine nucleotide (T-column, MilliGen/Bioscience # 0615.50) and was programmed to synthesize the sequences shown in Table I for each of ten 15 columns in independent reaction sets. The sequence of the last three monomers (from right to left since synthesis proceeds 3' to 5') encode the indicated amino acids:

Table I

	<u>Column</u>	<u>Sequence</u> (5' to 3')	<u>Amino Acids</u>
20	column 1R	(T/G)TTGAGCT	Phe and Val
	column 2R	(T/C)CTGAGCT	Ser and Pro
	column 3R	(T/C)ATGAGCT	Tyr and His
	column 4R	(T/C)GTGAGCT	Cys and Arg
25	column 5R	(C/A)TGGAGCT	Leu and Met
	column 6R	(C/G)AGGAGCT	Gln and Glu
	column 7R	(A/G)CTGAGCT	Thr and Ala
	column 8R	(A/G)ATGAGCT	Asn and Asp
	column 9R	(T/G)GGGAGCT	Trp and Gly
30	column 1R	A(T/A)AGAGCT	Ile and Cys

where the two monomers in parentheses denote a single monomer position within the codon and indicate that an equal mixture of each monomer was added to the reaction for

coupling. The monomer coupling reactions for each of the 10 columns were performed as recommended by the manufacturer (amidite version S1.06, # 8400-050990, scale 1 μ M). After the last coupling reaction, the columns were 5 washed with acetonitrile and lyophilized to dryness.

Following synthesis, the plugs were removed from each column using a decrimper and the reaction products were poured into a single weigh boat. Initially the bead mass increases, due to the weight of the monomers, however, at 10 later rounds of synthesis material is lost. In either case, the material was equalized with underivatized control pore glass and mixed thoroughly to obtain a random distribution of all twenty codon species. The reaction products were then aliquotted into 10 new reaction columns 15 by removing 25 mg of material at a time and placing it into separate reaction columns. Alternatively, the reaction products can be aliquotted by suspending the beads in a liquid that is dense enough for the beads to remain dispersed, preferably a liquid that is equal in density to 20 the beads, and then aliquoting equal volumes of the suspension into separate reaction columns. The lip on the inside of the columns where the frits rest was cleared of material using vacuum suction with a syringe and 25 G needle. New frits were placed onto the lips, the plugs 25 were fitted into the columns and were crimped into place using a crimper.

Synthesis of the second codon position was achieved using the above 10 columns containing the random mixture of reaction products from the first codon synthesis. The 30 monomer coupling reactions for the second codon position are shown in Table II. An A in the first position means that any monomer can be programmed into the synthesizer. At that position, the first monomer position is not coupled by the synthesizer since the software assumes that the 35 monomer is already attached to the column. An A also

denotes that the columns from the previous codon synthesis should be placed on the synthesizer for use in the present synthesis round. Reactions were again sequentially repeated for each column as shown in Table II and the 5 reaction products washed and dried as described above.

Table II

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
10	column 1R	(T/G)TTA	Phe and Val
	column 2R	(T/C)CTA	Ser and Pro
	column 3R	(T/C)ATA	Tyr and His
	column 4R	(T/C)GTA	Cys and Arg
15	column 5R	(C/A)TGA	Leu and Met
	column 6R	(C/G)AGA	Gln and Glu
	column 7R	(A/G)CTA	Thr and Ala
	column 8R	(A/G)ATA	Asn and Asp
20	column 9R	(T/G)GGA	Trp and Gly
	column 10R	A(T/A)AA	Ile and Cys

Randomization of the second codon position was achieved by 20 removing the reaction products from each of the columns and thoroughly mixing the material. The material was again divided into new reaction columns and prepared for monomer coupling reactions as described above.

Random synthesis of the next seven codons (positions 25 3 through 9) proceeded identically to the cycle described above for the second codon position and again used the monomer sequences of Table II. Each of the newly repacked columns containing the random mixture of reaction products from synthesis of the previous codon position was used for 30 the synthesis of the subsequent codon position. After synthesis of the codon at position nine and mixing of the reaction products, the material was divided and repacked into 40 different columns and the monomer sequences shown in Table III were coupled to each of the 40 columns in

independent reactions. The oligonucleotides from each of the 40 columns were mixed once more and cleaved from the control pore glass as recommended by the manufacturer.

Table III

5

	<u>Column</u>	<u>Sequence (5' to 3')</u>
	column 1R	AATTCTTTA
	column 2R	AATTCTGTTA
	column 3R	AATTCTGTTA
10	column 4R	AATTCTGGTTA
	column 5R	AATTCTTCTA
	column 6R	AATTCTCCTA
	column 7R	AATTCTGTCTA
	column 8R	AATTCTGCCTA
15	column 9R	AATTCTTATA
	column 10R	AATTCTCATA
	column 11R	AATTCTGTATA
	column 12R	AATTCTGCATA
	column 13R	AATTCTTGTA
20	column 14R	AATTCTCGTA
	column 15R	AATTCTGTGTA
	column 16R	AATTCTGCGTA
	column 17R	AATTCTCTGTA
	column 18R	AATTCTATGTA
25	column 19R	AATTCTGCTGTA
	column 20R	AATTCTGATGTA
	column 21R	AATTCTCAGA
	column 22R	AATTCTGAGA
	column 23R	AATTCTGCAGA
30	column 24R	AATTCTGGAGA
	column 25R	AATTCTACTA
	column 26R	AATTCTGCTA
	column 27R	AATTCTGACTA
	column 28R	AATTCTGGCTA
35	column 29R	AATTCTAAATA
	column 30R	AATTCTGTATA

	column 31R	<u>AATTCGAATA</u>
	column 32R	<u>AATTCGGATA</u>
	column 33R	<u>AATTCTTGGGA</u>
	column 34R	<u>AATTCTGGGA</u>
5	column 35R	<u>AATTCGTGGA</u>
	column 36R	<u>AATTCGGGGGA</u>
	column 37R	<u>AATTCTATAAA</u>
	column 38R	<u>AATTCTAAAA</u>
	column 39R	<u>AATTCGATAAA</u>
10	column 40R	<u>AATTCGAAAA</u>

Left half synthesis of random oligonucleotides proceeded similarly to the right half synthesis. This half of the oligonucleotide corresponds to the anti-sense sequence of the encoded randomized peptides. Thus, the 15 complementary sequence of the codons in Tables I through III are synthesized. The left half oligonucleotides also have 5 monomers at their 3' end of the sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 5'AATTCCAT3'. The rounds of synthesis, washing, drying, 20 mixing, and dividing are as described above.

For the first codon position, the synthesizer was fitted with a T-column and programmed to synthesize the sequences shown in Table IV for each of ten columns in independent reaction sets. As with right half synthesis, 25 the sequence of the last three monomers (from right to left) encode the indicated amino acids:

Table IV

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
5	column 1L	AA(A/C)GAGCT	Phe and Val
	column 2L	AG(A/G)GAGCT	Ser and Pro
	column 3L	AT(A/G)GAGCT	Tyr and His
	column 4L	AC(A/G)GAGCT	Cys and Arg
	column 5L	CA(G/T)GAGCT	Leu and Met
	column 6L	CT(G/C)GAGCT	Gln and Glu
10	column 7L	AG(T/C)GAGCT	Thr and Ala
	column 8L	AT(T/C)GAGCT	Asn and Asp
	column 9L	CC(A/C)GAGCT	Trp and Gly
	column 10L	T(A/T)TGAGCT	Ile and Cys

Following washing and drying, the plugs for each column
15 were removed, mixed and aliquotted into ten new reaction
columns as described above. Synthesis of the second codon
position was achieved using these ten columns containing
the random mixture of reaction products from the first
codon synthesis. The monomer coupling reactions for the
20 second codon position are shown in Table V.

Table V

	<u>Column</u>	<u>Sequence (5' to 3')</u>	<u>Amino Acids</u>
25	column 1L	AA(A/C)A	Phe and Val
	column 2L	AG(A/G)A	Ser and Pro
	column 3L	AT(A/G)A	Tyr and His
	column 4L	AC(A/G)A	Cys and Arg
	column 5L	CA(G/T)A	Leu and Met
	column 6L	CT(G/C)A	Gln and Glu
30	column 7L	AG(T/C)A	Thr and Ala
	column 8L	AT(T/C)A	Asn and Asp
	column 9L	CC(A/C)A	Trp and Gly
	column 10L	T(A/T)TA	Ile and Cys

Again, randomization of the second codon position was achieved by removing the reaction products from each of the columns and thoroughly mixing the beads. The beads were repacked into ten new reaction columns.

5 Random synthesis of the next seven codon positions proceeded identically to the cycle described above for the second codon position and again used the monomer sequences of Table V. After synthesis of the codon at position nine and mixing of the reaction products, the material was
10 divided and repacked into 40 different columns and the monomer sequences shown in Table VI were coupled to each of the 40 columns in independent reactions.

Table VI

	<u>Column</u>	<u>Sequence (5' to 3')</u>
15	column 1L	AATTCCATAAAAXXA
	column 2L	AATTCCATAAACXXA
	column 3L	AATTCCATAACAXXA
	column 4L	AATTCCATAACCXXA
	column 5L	AATTCCATAGAAXXA
20	column 6L	AATTCCATAGACXXA
	column 7L	AATTCCATAGGAXXA
	column 8L	AATTCCATAGGCXXA
	column 9L	AATTCCATATAAXXA
	column 10L	AATTCCATATACXXA
25	column 11L	AATTCCATATGAXXA
	column 12L	AATTCCATATGCXXA
	column 13L	AATTCCATACAAXXA
	column 14L	AATTCCATACACXXA
	column 15L	AATTCCATACGAXXA
30	column 16L	AATTCCATACGCXXA
	column 17L	AATTCCATCAGAXXA
	column 18L	AATTCCATCAGCXXA
	column 19L	AATTCCATCATAAXXA
	column 20L	AATTCCATCATCXXA

	column 21L	<u>AATTCCATCTGAXXA</u>
	column 22L	<u>AATTCCATCTGCXXA</u>
	column 23L	<u>AATTCCATCTCAXXA</u>
	column 24L	<u>AATTCCATCTCCXXA</u>
5	column 25L	<u>AATTCCATAGTAXXA</u>
	column 26L	<u>AATTCCATAGTCXXA</u>
	column 27L	<u>AATTCCATAGCAXXA</u>
	column 28L	<u>AATTCCATAGGCCXXA</u>
	column 29L	<u>AATTCCATATTAXXA</u>
10	column 30L	<u>AATTCCATATTCTXXA</u>
	column 31L	<u>AATTCCATATCAXXA</u>
	column 32L	<u>AATTCCATATCCXXA</u>
	column 33L	<u>AATTCCATCCAAXXA</u>
	column 34L	<u>AATTCCATCCACXXA</u>
15	column 35L	<u>AATTCCATCCCAXXA</u>
	column 36L	<u>AATTCCATCCCCXXA</u>
	column 37L	<u>AATTCCATTATAAXXA</u>
	column 38L	<u>AATTCCATTATCXXA</u>
	column 39L	<u>AATTCCATTTTAXXA</u>
20	column 40L	<u>AATTCCATTTCXXA</u>

The first two monomers denoted by an "X" represent an equal mixture of all four nucleotides at that position. This is necessary to retain a relatively unbiased codon sequence at the junction between right and left half oligonucleotides.

25 The above right and left half random oligonucleotides were cleaved and purified from the supports and used in constructing the surface expression libraries below.

Vector Construction

Two M13-based vectors, M13IX42 and M13IX22, were 30 constructed for the cloning and propagation of right and left half populations of random oligonucleotides, respectively. The vectors were specially constructed to facilitate the random joining and subsequent expression of right and left half oligonucleotide populations. Each

vector within the population contains one right and one left half oligonucleotide from the population joined together to form a single contiguous oligonucleotide with random codons which is twenty-two codons in length. The 5 resultant population of vectors are used to construct a surface expression library.

M13IX42, or the right-half vector, was constructed to harbor the right half populations of randomized oligonucleotides. M13mp18 (Pharmacia, Piscataway, NJ) was 10 the starting vector. This vector was genetically modified to contain, in addition to the encoded wild type M13 gene VIII already present in the vector: (1) a pseudo-wild type M13 gene VIII sequence with a stop codon (amber) placed between it and an Eco RI-Sac I cloning site for randomized 15 oligonucleotides; (2) a pair of Fok I sites to be used for joining with M13IX22, the left-half vector; (3) a second amber stop codon placed on the opposite side of the vector than the portion being combined with the left-half vector; and (4) various other mutations to remove redundant 20 restriction sites and the amino terminal portion of Lac Z.

The pseudo-wild type M13 gene VIII was used for surface expression of random peptides. The pseudo-wild type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has 25 been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the 30 same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene VIII therefore reduces the 35 possibility of non-viable phage production from the random peptide fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table VII.

5

TABLE VIIPseudo-Wild Type Gene VIII Oligonucleotide Series

	<u>Top Strand Oligonucleotides</u>	<u>Sequence (5' to 3')</u>
10	VIII 03	GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT GC
	VIII 04	A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAC A
	VIII 05	TT GGC TAC GCT TGG GCT ATG GTA GTA GTT ATA GTT
15	VIII 06	GGT GCT ACC ATA GGG ATT AAA TTA TTC AAA AAG TT
	VIII 07	T ACG AGC AAG GCT TCT TA
	<u>Bottom Strand Oligonucleotides</u>	
20	VIII 08	AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA TTT
	VIII 09	AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT
	VIII 10	AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG
25	VIII 11	C CTG TAA ACT ATT GAA TGC AGC CTT AGC AGG GTC
	VIII 12	ATC GCC TTC AGC CTA G

Except for the terminal oligonucleotides VIII 03 and 30 VIII 08, the above oligonucleotides (oligonucleotides VIII 04-VIII 07 and 09-12) were mixed at 200 ng each in 10 μ l

final volume and phosphorylated with T4 polynucleotide Kinase (Pharmacia, Piscataway, NJ) with 1 mM ATP at 37°C for 1 hour. The reaction was stopped at 65°C for 5 minutes. Terminal oligonucleotides were added to the 5 mixture and annealed into double-stranded form by heating to 65°C for 5 minutes, followed by cooling to room temperature over a period of 30 minutes. The annealed oligonucleotides were ligated together with 1.0 U of T4 DNA ligase (BRL). The annealed and ligated oligonucleotides 10 yield a double-stranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The double- 15 stranded insert was phosphorylated using T4 DNA Kinase (Pharmacia, Piscataway, NJ) and ATP (10 mM Tris-HCl, pH 7.5, 10 mM MgCl₂) and cloned in frame with the Eco RI and Sac I sites within the M13 polylinker. To do so, M13mp18 was digested with Bam HI (New England Biolabs, Beverley, 20 MA) and Hind III (New England Biolabs) and combined at a molar ratio of 1:10 with the double-stranded insert. The ligations were performed at 16°C overnight in 1X ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl₂, 20 mM DTT, 1 mM ATP, 50 µg/ml BSA) containing 1.0 U of T4 DNA ligase (New 25 England Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the right-half vector to yield functional M13IX42. The mutations were 30 generated using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was 35 performed as recommended by the manufacturer.

A Fok I site used for joining the right and left halves was generated 8 nucleotides 5' to the unique Eco RI site using the oligonucleotide 5'-CTCGAATTCTGTACATCCTGGTCATAGC-3'. The second Fok I site retained in the vector 5 is naturally encoded at position 3547; however, the sequence within the overhang was changed to encode CTTC. Two Fok I sites were removed from the vector at positions 239 and 7244 of M13mp18 as well as the Hind III site at the end of the pseudo gene VIII sequence using the mutant 10 oligonucleotides 5'-CATTTCAGATGGCTTAGA -3' and 5'-TAGCATTAAACGTCCAATA-3', respectively. New Hind III and Mlu I sites were also introduced at position 3919 and 3951 of M13IX42. The oligonucleotides used for this mutagenesis had the sequences 5'-ATATATTAGTAAGCTTCATCTTCT-3' and 5'- 15 GACAAAGAACGCGTAAAACTTT-3', respectively. The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the mutant oligonucleotide 5'-GCAGGGCCTCTCGCTATTGCTTAAGAACGCTTGCT-3'. This deletion also removed a third M13mp18 derived Fok I site. The distance 20 between the Eco RI and Sac I sites was increased to ensure complete double digestion by inserting a spacer sequence. The spacer sequence was inserted using the oligonucleotide 5'-TTCAGCCTAGGATCCGCCGAGCTCTCCTACCTGCGAATTCTGTACATCC-3'. Finally, an amber stop codon was placed at position 4492 25 using the mutant oligonucleotide 5'-TGGATTATACTTCTAAATAATGGA-3'. The amber stop codon is used as a biological selection to ensure the proper recombination of vector sequences to bring together right and left halves of the randomized oligonucleotides. In constructing the above 30 mutations, all changes made in a M13 coding region were performed such that the amino acid sequence remained unaltered. It should be noted that several mutations within M13mp18 were found which differed from the published sequence. Where known, these sequence differences are 35 recorded herein as found and therefore may not correspond exactly to the published sequence of M13mp18.

The sequence of the resultant vector, M13IX42, is shown in Figure 5. Figure 3A also shows M13IX42 where each of the elements necessary for producing a surface expression library between right and left half randomized 5 oligonucleotides is marked. The sequence between the two Fok I sites shown by the arrow is the portion of M13IX42 which is to be combined with a portion of the left-half vector to produce random oligonucleotides as fusion proteins of gene VIII.

10 M13IX22, or the left-half vector, was constructed to harbor the left half populations of randomized oligonucleotides. This vector was constructed from M13mp19 (Pharmacia, Piscataway, NJ) and contains: (1) Two Fok I sites for mixing with M13IX42 to bring together the left 15 and right halves of the randomized oligonucleotides; (2) sequences necessary for expression such as a promoter and signal sequence and translation initiation signals; (3) an Eco RI-Sac I cloning site for the randomized oligonucleotides; and (4) an amber stop codon for 20 biological selection in bringing together right and left half oligonucleotides.

Of the two Fok I sites used for mixing M13IX22 with M13IX42, one is naturally encoded in M13mp18 and M13mp19 (at position 3547). As with M13IX42, the overhang within 25 this naturally occurring Fok I site was changed to CTTC. The other Fok I site was introduced after construction of the translation initiation signals by site-directed mutagenesis using the oligonucleotide 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3'.

30 The translation initiation signals were constructed by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table VIII and were ligated

as a double-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the pseudo gene VIII insert. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 and the translation initiation codon 5 (ATG) is the first three nucleotides of oligonucleotide 016.

TABLE VIII

Oligonucleotide Series for Construction of
Translation Signals in M13IX22

	<u>Oligonucleotide</u>	<u>Sequence (5' to 3')</u>
10	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG GCA
		GCC GCT GGA TTG TT
15	017	ATTA CTC GCT GCC CAA CCA GCC ATG
		GCC GAG CTC GTG AT
	018	GACC CAG ACT CCA GATATC CAA CAG
		GAA TGA GTG TTA AT
	019	TCT AGA ACG CGT C
20	020	ACGT G ACG CGT TCT AGA AT TAA
		CACTCA TTC CTG T
	021	TG GAT ATC TGG AGT CTG GGT CAT
		CAC GAG CTC GGC CAT G
	022	GC TGG TTG GGC AGC GAG TAA TAA
		CAA TCC AGC GGC TGC C
25	023	GT AGG CAA TAG GTA TTT CAT TAT
		GAC TGT CCT TGG CG

Oligonucleotide 017 contained a Sac I restriction site 67 nucleotides downstream from the ATG codon. The naturally occurring Eco RI site was removed and a new site introduced 30 25 nucleotides downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTGGCGTGTGAAATTGTTA-3' and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCT

GGGT-3 were used to generate each of the mutations, respectively. An amber stop codon was also introduced at position 3263 of M13mp18 using the oligonucleotide 5'-CAATTTATCCTAAATCTTACCAAC-3'.

5 In addition to the above mutations, a variety of other modifications were made to remove certain sequences and redundant restriction sites. The LAC Z ribosome binding site was removed when the original Eco RI site in M13mp18 was mutated. Also, the Fok I sites at positions 239, 6361
10 and 7244 of M13mp18 were likewise removed with mutant oligonucleotides 5'-CATTTCAGATGGCTTAGA-3', 5'-CGAAAGGGGGTGTGCTGCAA-3' and 5'-TAGCATTAAACGTCCAATA-3', respectively. Again, mutations within the coding region did not alter the amino acid sequence.

15 The resultant vector, M13IX22, is 7320 base pairs in length, the sequence of which is shown in Figure 6. The Sac I and Eco RI cloning sites are at positions 6290 and 6314, respectively. Figure 3A also shows M13IX22 where each of the elements necessary for producing a surface
20 expression library between right and left half randomized oligonucleotides is marked.

Library Construction

Each population of right and left half randomized oligonucleotides from columns 1R through 40R and columns 1L
25 through 40L are cloned separately into M13IX42 and M13IX22, respectively, to create sublibraries of right and left half randomized oligonucleotides. Therefore, a total of eighty sublibraries are generated. Separately maintaining each population of randomized oligonucleotides until the final
30 screening step is performed to ensure maximum efficiency of annealing of right and left half oligonucleotides. The greater efficiency increases the total number of randomized oligonucleotides which can be obtained. Alternatively, one

can combine all forty populations of right half oligonucleotides (columns 1R-40R) into one population and of left half oligonucleotides (columns 1L-40L) into a second population to generate just one sublibrary for each.

5 For the generation of sublibraries, each of the above populations of randomized oligonucleotides are cloned separately into the appropriate vector. The right half oligonucleotides are cloned into M13IX42 to generate sublibraries M13IX42.1R through M13IX42.40R. The left half
10 oligonucleotides are similarly cloned into M13IX22 to generate sublibraries M13IX22.1L through M13IX22.40L. Each vector contains unique Eco RI and Sac I restriction enzyme sites which produce 5' and 3' single-stranded overhangs, respectively, when digested. The single strand overhangs
15 are used for the annealing and ligation of the complementary single-stranded random oligonucleotides.

The randomized oligonucleotide populations are cloned between the Eco RI and Sac I sites by sequential digestion and ligation steps. Each vector is treated with an excess
20 of Eco RI (New England Biolabs) at 37°C for 2 hours followed by addition of 4-24 units of calf intestinal alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN). Reactions are stopped by phenol/chloroform extraction and ethanol precipitation. The pellets are resuspended in
25 an appropriate amount of distilled or deionized water (dH₂O). About 10 pmol of vector is mixed with a 5000-fold molar excess of each population of randomized oligonucleotides in 10 µl of 1X ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl₂, 20 mM DTT, 1 mM ATP, 50 µg/ml BSA)
30 containing 1.0 U of T4 DNA ligase (BRL, Gaithersburg, MD). The ligation is incubated at 16°C for 16 hours. Reactions are stopped by heating at 75°C for 15 minutes and the DNA is digested with an excess of Sac I (New England Biolabs) for 2 hours. Sac I is inactivated by heating at 75°C for
35 15 minutes and the volume of the reaction mixture is

adjusted to 300 μ l with an appropriate amount of 10X ligase buffer and dH₂O. One unit of T4 DNA ligase (BRL) is added and the mixture is incubated overnight at 16°C. The DNA is ethanol precipitated and resuspended in TE (10 mM Tris-HCl, 5 pH 8.0, 1 mM EDTA). DNA from each ligation is electroporated into XL1 Blue™ cells (Stratagene, La Jolla, CA), as described below, to generate the sublibraries.

E. coli XL1 Blue™ is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cells are prepared by inoculating a fresh colony of XL1s into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KCl, dH₂O to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD₅₅₀ is 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended 20 in 500 ml of ice-cold 10% (v/v) sterile glycerol and centrifuged and resuspended a second time in the same manner. After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the OD₅₅₀ of the suspension is 200 to 25 300. Usually, resuspension is achieved in the 10% glycerol that remains in the bottle after pouring off the supernate. Cells are frozen in 40 μ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

Frozen cells are electroporated by thawing slowly on 30 ice before use and mixing with about 10 pg to 500 ng of vector per 40 μ l of cell suspension. A 40 μ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 200 Ω parallel resistor, 25 μ F, 1.88 kV, which gives a pulse length (τ) of 35 ~4 ms. A 10 μ l aliquot of the pulsed cells are diluted

into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl₂ and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

5 Each of the eighty sublibraries are cultured using methods known to one skilled in the art. Such methods can be found in Sanbrook et al., Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current 10 Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml sublibrary cultures were grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 15 37°C for 5-8 hours. The bacteria were pelleted by centrifugation at 10,000 xg. The supernatant containing phage was transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing right and left half randomized oligonucleotide inserts is isolated from 20 the cell pellet of each sublibrary. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 25 mg/μl lysozyme is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% SDS is added followed by 10 minutes on ice. The suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are centrifuged at 15,000 rpm for 15 30 minutes at 4°C, RNased and extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of CsCl₂ is dissolved into each tube until a density of 1.60 g/ml is achieved. EtBr is added to 600 μg/ml and the 35 double-stranded DNA is isolated by equilibrium

centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half sublibrary are used to generate forty libraries in which the right and left halves of the randomized 5 oligonucleotides have been randomly joined together.

Each of the forty libraries are produced by joining together one right half and one left half sublibrary. The two sublibraries joined together corresponded to the same column number for right and left half random 10 oligonucleotide synthesis. For example, sublibrary M13IX42.1R is joined with M13IX22.1L to produce the surface expression library M13IX.1RL. In the alternative situation where only two sublibraries are generated from the combined populations of all right half synthesis and all left half 15 synthesis, only one surface expression library would be produced.

For the random joining of each right and left half oligonucleotide populations into a single surface expression vector species, the DNAs isolated from each 20 sublibrary are digested an excess of Fok I (New England Biolabs). The reactions are stopped by phenol/chloroform extraction, followed by ethanol precipitation. Pellets are resuspended in dH₂O. Each surface expression library is generated by ligating equal molar amounts (5-10 pmol) of 25 Fok I digested DNA isolated from corresponding right and left half sublibraries in 10 μ l of 1X ligase buffer containing 1.0 U of T4 DNA ligase (Bethesda Research Laboratories, Gaithersburg, MD). The ligations proceed overnight at 16°C and are electroporated into the sup 0 30 strain MK30-3 (Boehringer Mannheim Biochemical, (BMB), Indianapolis, IN) as previously described for XL1 cells. Because MK30-3 is sup 0, only the vector portions encoding the randomized oligonucleotides which come together will produce viable phage.

EXAMPLE II

Expression of unbound MHC Class I molecules.

D. melanogaster lacks a conventional immune system, and MHC genes have not been identified in this species.

5 Auxiliary proteins required for loading peptide onto class I molecules in mammalian cells are encoded in the MHC region; it therefore seemed likely that *Drosophila* cells transfected with cDNAs encoding the class I subunits would express class I molecules free of peptide. cDNAs encoding

10 various mouse and human class I subunits were cloned downstream of the metallothionein promoter in the *Drosophila* expression vector pRMHa3. Stable cell lines transfected with the recombinant plasmids encoding heavy chain and β_2m were established. Flow cytometry analyses

15 with anti-class I antibodies showed that surface expression of the various MHC class I molecules in these lines was copper-dependent. Since binding by these antibodies requires β_2m to be associated with the heavy chain, we obviously detected expression of the heterodimer. To

20 determine whether the expressed molecules were free of peptide, we took advantage of the fact that empty class I molecules are more thermolabile than peptide-containing molecules. To this end we immunoprecipitated class I molecules from the *Drosophila* cells after exposing lysates

25 for 1 hr to either 4°C or 37°C. Prior to these incubations, peptides known to bind to the various class I molecules were added to the lysates. SDS/PAGE analyses of the immunoprecipitated class I molecules indicated that at 4°C all the class I molecules were stable. The class I

30 molecules run as a doublet on SDS/PAGE due to trimming of the N-linked carbohydrates in the Golgi. After incubation at 37°C, few if any class I molecules were immunoprecipitated unless peptide with affinity for the class I molecules had been added or antibodies (antisera 193) that do not rely on class I conformation were used.

35 The temperature-sensitive nature of the expressed class I molecules was confirmed by flow cytometry. At 37°C class

I molecules vanished from the cell surface unless they had been exposed to peptide that binds. These results demonstrate that human and mouse MHC class I molecules expressed in *Drosophila* cells display all the hallmarks of 5 empty molecules.

EXAMPLE III

Chemical Modification of Terminal Residue

A phage display library, made by the method of Example I was chemically modified so as to formylate the N terminal residues using the 22980X kit from Pierce Chemical Co., according to the manufacturer's instructions. Briefly, 2 mg precipitated peptides as made in Example I was dissolved in 0.1m 2[N-morpholino] ethane sulfuric acid, pH 4.5 to 5.0 10 50 mM of HCO₂Na was dissolved in 500 ml of the same buffer, 50 to which 200 μ l of the BSA solution was added. 10 Mg of EDC (1-ethyl -3-(3-dimethyl-aminopropyl)carbodiimide hydrochloride) was added and dissolved by mixing. The solution was incubated for 2 hours at room temperature and purified by gel filtration. A 10 ml desalting column was 15 equilibrated with serial column volume purification batter (0.083 M. sodium phosphates, 0.9 M NaCl, pH7 and the sample added. 0.5 ml aliquots were added to the column and the fractions collected in separate tubes. The fractions containing the conjugates were determined by measuring the 20 absorbance at 200 nm. The procedure is depicted 25 schematically in Figure ____.

EXAMPLE IV

Selection of peptides binding to K^{bml} and K^{bms}.

The K^{bml} mutants of the K^b class I molecule were 30 originally identified on the basis of alloreactivity. The K^{bml} and K^{bms} class I molecules have three single amino acid changes in regions of the molecules involved in peptide binding. Changes in the K^{bms} molecule also interfere with association with β_2 m.

Similar to the peptides identified with the K^b molecule, the peptides identified from with the K^{bm1} molecule show a preference for serine, isoleucine or valine residues at the N-terminal peptide position (78%). However, 5 aromatic amino acids at peptide P3 position occur with less than half the frequency of that observed with the K^b molecule (34% vs. 92%), and tyrosine is not seen at this P3 position. This is consistent with crystal structure data. Prelacements at Glu152Tyr and Arg155Ala in the K^{bm1} molecule 10 are expected to eliminate hydrogen bond formation between a peptide tyrosine side chain hydroxyl group, and the $O\epsilon 1$ group of glutamic acid, and $N\epsilon, N\eta 1, N\eta 2$ groups of arginine, respectively. This result is also consistent with the inability of the K^{bm1} mutant to present the VSV-8 peptide, 15 RGYVY!GL, to cytotoxic T lymphocytes, and with our results with soluble peptide in competition studies (see below) which suggest that the peptide presented by phage clone B1, VGYDFGGSQLKG, binds very poorly to the K^{bm1} molecule (Fig. 1 and Fig. 3).

20 The K^{bm8} molecule was more difficult to screen due to the instability of the empty soluble heterodimer. However, nine independent clones were identified (Fig. 1 and Table 1c). One N-terminal random peptide sequence predominates, however, it is clear from the C-terminal random peptide 25 sequences of these clones that they are derived from independently assembled random peptide clones. As with the peptide binding motifs identified with K^b and K^{bm1} , the aromatic residues are seen at the peptide P3 and P5 positions. Similar to the peptides identified with the K^b 30 molecule, and unlike peptides identified with the K^{bm1} , tyrosine is an observed amino acid at the P3 position in clones identified with K^{bm8} consistent with the ability of K^{bm8} in presenting the VSV-8 peptide, RGYVYQGL, to cytotoxic T lymphocytes.

The A-2 clone identified with K^{bms} differs from any of the peptide sequences which bind to the K^b and K^{bml} molecules (Table 1c) with the presence of an N-terminal tryptophan residue.

5

EXAMPLE V

Peptide competition studies

Screening all clones with each of the allotypic variants by means of the phage filter lift assay identifies both class I \jmath -specific and cross-binding peptides.

10 Solution peptide competition studies confirm the differential data obtained from the filter lifts, and support peptide binding sensitivity for the filter lift assay in the hundred nanomolar range. For example, clone K2, SQWEHYSFDVMG, which was identified from the phage

15 library with the K^{bms} molecule, and appears to bind with specificity to the K^{bms} molecule when screened by filter lift assay, shows this preference in solution competition experiments. Clone I-6, (IGPCFFCAS), identified by screening with the K^{bml} molecule, binds well to both the K^b

20 and K^{bml} molecules. Competition studies with the soluble peptides confirm the results obtained with the phage displayed peptides. In every case densitometer readings taken from filter lift assays which yield measurements in the range of 10 units corresponded to solution competition

25 results which yielded corresponding values in the range of 10^{-8} Molar.

The nature of the linker sequence and other parameters involved with protein presentation by phage display mechanism(s) (e.g. efficiency of infection, phage coat

30 assembly or quantitative differences in displayed peptide) are likely to impact the screening of libraries, and, therefore, the sequence data obtained. However, the fact that both the relative intensities of signals and the differential binding results obtained from the filter lift

35 assays are confirmed by solution peptide competition

experiments supports the identification of class I peptide binding motifs by this method.

The I6 peptide sequence is very similar to the sequence of the K^b-binding peptide SEV-9, and may bind to K^b 5 in a manner similar to the binding of the SEV-9 peptide, with the phenylalanine occupying the pocket which is generally occupied by the P5 side chain in eight amino acid binding peptides.

TABLE IX

Clone:	Peptide:	K^b :	K^b :	K^b :
I6:	IGPCFFCASDKG	1.6×10^{-7}	(345) **	1.9×10^{-8} (3428)
K2:	SQWEHYSFDVMG	2.4×10^{-6}	(--)	2.4×10^{-5} (--)
6	F1:	4.6×10^{-7}	(137)	4.0×10^{-8} (3243)
D2:	SIYKFFEYHFEQ	1.1×10^{-8}	(3558)	3.8×10^{-7} (228)
B1:	VGYDFGGSQLKG	2.9×10^{-8}	(3205)	3.8×10^{-6} (--)

** - densitometer reading from filter lift assay of phage-displayed peptide clone.
 * - estimated value; outside of measuring range.

The possibility of bias in the results obtained from the construction, expression and screening of a random library is impossible to exclude. However, the methods used for construction of codon-based peptide libraries 5 makes it possible to identify clones which were synthetic partners during random oligonucleotide synthesis. The random clones identified by the class I molecules in this study appear to represent a selected population which describe peptide motifs which arise from binding selection 10 without bias from construction or expression of the library members.

EXAMPLE VI

Hmt is one of a number of 'nonclassical' class I molecules encoded outside the MHC. The Hmt molecule is 15 known to bind and present an N-formylated peptide derived from a subunit of the mitochondrial- encoded NADH dehydrogenase, ND1, an hydrophobic N-formylated peptides. Screening libraries with Hmt using methods described, above, identifies peptides expressed from incomplete 20 oligonucleotide synthesis contaminants in the phage display libraries (Fig. 2a). These peptides are characterized by transnational termination and reinitiation events resulting in N-terminal N-formyl methionine residues. Processing, transport, and assembly of these aberrant peptide-gene VIII 25 fusion proteins must occur in the absence of encoded signal sequences. However, it is important to remove any bias which may occur with the phage presentation of aberrant gene VIII fusion peptides, so we developed a chemical formylation protocol which results in the N-formylation of 30 the random peptides following normal protein expression and processing.

This alternate method of screening relies on chemical N-formylation prior to panning and phage lifts, and identifies random peptides which do not bind to the Hmt

molecule unless chemically formulated (Fig. 2b). With this method we have identified peptides which have N-terminal methionine residues (Fig. 2c).

The following references are incorporated in their entirety.

1. Schumacher, T.N. Nature 350, 703-706 (1991).
2. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.G. Nature 351, 290-296 (1991).
3. Rammensee, H.G., Falk, K. & Rotzschke, O. A. Rev. Immun. 11, 213-244 (1993).
4. Saito, Y., Peterson, P.A. & Matsumura, M. J. Biol. Chem. 268, 21309-21317 (1993).
5. Silver, M.L., Guo, H.C., Strominger, J.L. & Wiley, D.C. Nature 360, 367-369 (1992).
6. Guo, H.D., Jardetsky, T.S., Garrett, T.P.J., Lane, W.S., Strominger, J.L. & Wiley, D.C. Nature 360, 364-366 (1992).
7. Fremont, D.H., Matsumura, M., Stura, E.A., Peterson, P.A. & Wilson, I.A. Science 257, 927-934 (1992).
8. Zhang, W., Young, A.C.M., Imarai, M., Nathenson, S.G., & Sacchettini, J.C. Proc. Natl. Acad. Sci. USA 89, 8403-8407 (1992).
9. Hammer, J., Valsasnini, P., Tolba, K., Bolin, D., Higelin, J., Takacs, B. & Sinigaglia, F. Cell 74, 197-203 (1993).
10. van Bleek, G.M. & Nathenson, S.G. Nature 348, 213-216 (1990).
11. Kast, W.M., Roux, L., et al. Proc. Natl. Acad. Sci. U.S.A. 88, 2283-2287 (1991).
12. Falk, K., Rotzschke, O., Deres, K., Metzger, J., Jung, G. & Rammensee, H.G. J. Exp. Med. 174, 425-434 (1991).
13. Oldstone, M.B.A. J. Virol. 65, 6381-6386 (1991).
14. Deres, K., Schumacher, T.N.M., Wiesmuller, K.H., Stevanovic, S., Greiner, G., Jung, G. & Ploegh, H.L. Eur. J. Immunol. 22, 1603-1608 (1992).
15. Koziowski, S., Corr, M., et al. J. Exp. Med. 175, 1417-1422 (1992).
16. Sherman, L.A., Burke, T.A. & Biggs, J.A. J. Exp. Med. 175, 1221-1226 (1992).
17. Monaco, J.J. Immunol. Today 13, 173-179 (1992).
18. Heemeis, M.T., Schumacher, T.N.M., Wonigeit, K. & Ploegh, H.L. Science 262, 2059-2063 (1993).
19. Momburg, F., Roeise, J., Howard, J.C., Butcher, G.W., Hammerling, G.J. & Neefjes, J.J. Nature 367, 648-651 (1994).
20. Nathenson, S.G., Geliebter, J., Pfaffenbach, G.M. & Zeff, R.A. Ann. Rev. Immunol. 4, 471-502 (1986).
21. Young, A.C.M., Zhang, W., Sacchettini, J.C. & Nathenson, S.G. Cell 76, 39-50 (1994).
22. van Bleek, G.M. & Nathenson, S.G. Proc. Natl. Acad. Sci. USA 88 11032-11036 (1991).
23. Shawar, S.M., Cook, R.G., Rodgers, J.R. & Rich, R.R. J. Exp. Med. 171, 897 (1990).

We Claim:

1. A method for identifying peptides capable of forming a loaded MHC molecules, comprising the steps of:
 - a. generating a library of random peptides expressed as fusion proteins on the surface of a cell or virus, said peptides being greater than about 8 amino acids in length;
 - b. screening said fusion proteins for binding to unbound MHC molecules; and
 - 10 c. obtaining the terminal octamers or nonamers of said peptides which bind to said MHC molecules.
2. The method of claim 1 further comprising the steps of:
 - a. detecting the sequence of the amino acids adjacent to the terminal octamers or nonamers of said random peptides which bind to MHC to identify appropriate tether sequences; and
 - 15 b. generating a library of random octamer or nonamers fused to said tether sequences.
- 20 3. A library of random peptides comprising octamers or nonamers attached to a tether sequence, said peptides expressed a fusion protein on the surface of a cell or virus, wherein said tether sequence can facilitate binding of said octamers or nonamers to said MHC molecules.
- 25 4. A library of random peptides comprising fusion peptides having chemically modified N-termini.

1/7






FIG. 1





4 / 7




FIG. 4

5/7

	123456789		123456789
VSV-8	<u>RGYVYQGL</u>	VSV-8	<u>RGYVYQGL</u>
OVA-8	SIINFEKL	OVA-8	SIINFEKL
SEV-9	FAPGNYPAL	SEV-9	FAPGNYPAL

B1	VGYDFGGSQLKG	D3	IGYDYSQDSSLG
B2	IGYDYSWNPPLG	D4	VSFEHFTARCWG
B3	IGYNYSGDPSSLG	D5	KIYNFCLACKWG
B4	ANYDFNQVQLQG	D6	VSFSFGAWHNPG
B5	INFDFWNKYNNSG	D7	VNFMDHHWRVG
B6	SIWDFTDVKTWG	D8	YAYAWGITDKLG
B7	VAPTFKSHQSVD	D9	SIIEFYWTKHMG
B8	LALTYTFPGLQG	D10	VGYDFGGSQLKG
C1	IGYDYSGILLRG	E1	SIWKHLTSASEG
C2	IGYDYSGNSPPG	E2	STYSFGRAEILG
C3	VIWDFVGNWRAG	E3	VNFIFIAQSMEG
C4	VGYVYGVPEYLG	E4	VIYQWAQVQNEG
C5	IGYDILEFSSGG	E5	MHYDFTGKGVVG
C6	VGYDYGSYGGLG	E6	SIYQFEHAELWG
C7	IGYDYSGILLRG	E7	SVFDFVQLKDLG
C8	VGYDFVRTGHLG	E8	CYQFQHAEELLG
C9	SSYAFENITFAG	E9	SIYKFWEHHVVG
D1	STYCFCSLCDGG	E10	SIYQFLFPITRG
D2	SIYKFFEYHFEG	F10	VGYDFGGSQMQG

FIG. 5

6/7

	<u>123456789</u>		<u>123456789</u>
VSV-8	RGYVYQGL	VSV-8	RGYVYQGL
OVA-8	SIINFEKL	OVA-8	SIINFEKL
SEV-9	FAPGNYPAL	SEV-9	FAPGNYPAL
<hr/>			
F1	SGIRYLNWCMSG	H3	SIAHFDWEWISG
F2	SSINFKIPVDWG	H4	SWWGVFSMNLGH
F3	SSWKYEIWDSDLG	H5	VSPTFGIWIIQG
F4	CTFGSCPREG	H6	VNFGWPWFODYEG
F5	GFVTFLQLQHSG	H7	SAPNYFKIIQAG
F6	VIFEGWHSICPG	H8	NVARFDPMNIRG
F7	VAPAFNYWNSWG	H9	VAPMYYISWILG
F8	SVFDFFQMINLG	H10	SSVKYEIWDSDLG
F9	KSPWYLSFGYSG	I1	VIVNFDMACMKG
G1	IGIDYGRLYNEG	I2	AWIFHTGFYCVG
G2	SAFQHIELTVGG	I3	VNFNFTAIHQWG
G3	SVFDFFQMINLG	I4	SITSFLSVGDRR
G4	VNVYYFTLINLG	I5	VGINYTYKNDEG
G5	IIMDFNHWVQQG	I6	IGPCFFCASDKG
G6	VSFVHWMSMDCTG	I7	TWIFHAGFYCRG
G7	SSFDFWALKNQG	I8	TGPIFNWRDWMG
G8	IWIDAMGWTYLG	I9	VNFWWWPVNHMG
G9	SIVEFLGKNQRG	J6	SWVGYYNGWCSG
G10	STLAFFTHICKG	J7	FNFDAAMHQLG
H1	SVIEFVPPPEGWG	J8	DASMVPHWNLEG
H2	VSFVHWMSMDCTG		

FIG. 6

123456789

K2	SQWEHYSFDVMG
A2	WGSMWMHITYPG
J3	HSYEYPMLDWLG
L2	SMYEFFSGLGG
L3	ASYCFYAAQGLG

FIG. 7

SUBSTITUTE SHEET (RULE 26)

7/7




FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/04509

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G01N 33/53, 33/68; C12Q 1/68
US CL : 435/6, 7.21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.21, 172.1; 436/501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG
search terms: phage library, peptide library, MHC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF EXPERIMENTAL MEDICINE, VOLUME 176, ISSUED OCTOBER 1992, HAMMER ET AL., "IDENTIFICATION OF A MOTIF FOR HLA-DR1 BINDING PEPTIDES USING M13 DISPLAY LIBRARIES", PAGES 1007-1012. SEE ABSTRACT AND PAGE 1011, SECOND COLUMN.	1-3
X	WO, A, 91/19818 (DOWER ET AL.) 26 DECEMBER 1991, SEE PAGE 19.	4

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier document published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search
15 JUNE 1995

Date of mailing of the international search report

26 JUN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

LORA M. GREEN

Telephone No. (703) 308-0196